TY - JOUR
T1 - Higher Risk of Hepatocellular Carcinoma Progression in the Population of Untreated Immune-Tolerant Phase Chronic Hepatitis B Patients: An Evidence Based
AU - Hasan, Irsan
PY - 2020
Y1 - 2020
N2 - Aim: This evidence-based case report is meant to comprehensively review the effect of antiviral treatment
in IT-phase CHB patients from available studies.
Method: Pubmed, ProQuest, Cochrane, Scopus, Sciencedirect and EBSCOhost were comprehensively searched for systematic review and cohort prognostic researches studying the impact of anti-virals treatmentfor CHB patients in IT-phase. Three studies were selected and critically appraised. Data were then summarized descriptively.
Results: The three studies included in this study were retrospective cohort studies. One study stated that the treated IT-phase group had significally reduced risk of HCC (HR = 2.54; 95% CI: 1.54 to 4.18; p < 0.001) compared to the treated immune-active (IA) phasegroup. The last study stated a higher adjusted hazard ratio (aHR) of the UIT in predicting HCC risk was 2.327 (95% CI 0.475–11.391; p = 0.297), if compared to the IA group.
Conclusion: While studies shows apparent results regarding the treatment of CHB patients in the IT-phase its benefeit in reducing cumulative incidence of HFCC, its clinincal advantage is soon to be discovered. The results were inconclusive, and the initiation of treatment in CHB patients within the IT-phase cannot yet be recommended until further research.
AB - Aim: This evidence-based case report is meant to comprehensively review the effect of antiviral treatment
in IT-phase CHB patients from available studies.
Method: Pubmed, ProQuest, Cochrane, Scopus, Sciencedirect and EBSCOhost were comprehensively searched for systematic review and cohort prognostic researches studying the impact of anti-virals treatmentfor CHB patients in IT-phase. Three studies were selected and critically appraised. Data were then summarized descriptively.
Results: The three studies included in this study were retrospective cohort studies. One study stated that the treated IT-phase group had significally reduced risk of HCC (HR = 2.54; 95% CI: 1.54 to 4.18; p < 0.001) compared to the treated immune-active (IA) phasegroup. The last study stated a higher adjusted hazard ratio (aHR) of the UIT in predicting HCC risk was 2.327 (95% CI 0.475–11.391; p = 0.297), if compared to the IA group.
Conclusion: While studies shows apparent results regarding the treatment of CHB patients in the IT-phase its benefeit in reducing cumulative incidence of HFCC, its clinincal advantage is soon to be discovered. The results were inconclusive, and the initiation of treatment in CHB patients within the IT-phase cannot yet be recommended until further research.
M3 - Article
SN - 2302-8181
JO - The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy
JF - The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy
ER -
